Dose-Dense Therapy in Aggressive Lymphoma - Full Text View

Purpose

To investigate if a dose-dense chemotherapy with weekly chemotherapy compared to standard treatment every 3 weeks results in better survival in aggressive non-Hodgkin's lymphoma.

Condition	Intervention
Lymphoma	Drug: CEOP/IMVP-Dexa chemotherapy

MedlinePlus related topics:

Lymphoma

ChemIDplus related topics:

Mesna Ifosfamide Etoposide Filgrastim Cyclophosphamide Dexamethasone Dexamethasone acetate Dexamethasone Sodium Phosphate Doxiproct plus Leucovorin Calcium Citrovorum factor Folinic acid calcium salt pentahydrate Leucovorin Methotrexate Prednisolone 6-Methylprednisolone Depo-medrol Medrol veriderm Methylprednisolone Methylprednisolone hemisuccinate Methylprednisolone Sodium Succinate Prednisolone acetate Prednisolone sodium phosphate Prednisolone Sodium Succinate Vincristine sulfate Vincristine Etoposide phosphate Epirubicin hydrochloride Epirubicin Calcium gluconate

U.S. FDA Resources

Study Type:	Expanded Access

Official Title:	Phase 3 Study of Dose-Dense Therapy Versus CHOP in Aggressive Non-Hodgkin's Lymphoma

Further study details as provided by Arbeitsgemeinschaft medikamentoese Tumortherapie:

Intervention Details:

Cyclophosphamide 750 mg/m2 i.v. d 1, epirubicin 70 mg/m2 i.v d 1, vincristine 1.4 mg/m2 i.v. d 1+8, prednisolone 100 mg p.o. d 1-5, ifosfamide 2000 mg/m2 i.v. d 15-17, etoposide 100 mg/m2 i.v. d 15-17, dexamethasone 40 mg p.o. or i.v. d 15-19, methotrexate 800 mg/m2 i.v. d 22. Mesna was given with ifosfamide, calcium-folinate rescue after methotrexate. Filgrastim was given on days 2-7, 9-12, 18-21, 23-28

Detailed Description:

Patients are randomized to receive dose-dense CEOP/IMVP-Dexa chemotherapy or standard 3-weekly CHOP.

Eligibility

Ages Eligible for Study:	18 Years to 70 Years
Genders Eligible for Study:	Both

Criteria

Inclusion Criteria:

18 and 70 years of age
Centrally reviewed, histologically proven diffuse large B-cell, anaplastic large-cell, or peripheral T-cell unspecified
Measurable disease
All stages

Exclusion Criteria:

Lymphoblastic or Burkitt histology
CNS-disease
HIV-positive
pregnant or lactating women
Pretreatment
Other malignancy
Concomitant diseases that forbid chemotherapy

Contacts and Locations

No Contacts or Locations Provided

More Information

Study ID Numbers:	NHL-5
First Received:	August 15, 2007
Last Updated:	August 15, 2007
ClinicalTrials.gov Identifier:	NCT00517894
Health Authority:	Austria: Federal Ministry for Health and Women

Keywords provided by Arbeitsgemeinschaft medikamentoese Tumortherapie:

lymphoma

aggressive

chemotherapy

dose-dense

Study placed in the following topic categories:

Dexamethasone

Immunoproliferative Disorders

Methylprednisolone

Lymphoma, small cleaved-cell, diffuse

Vincristine

Leucovorin

Methylprednisolone acetate

Prednisolone acetate

Cyclophosphamide

Epirubicin

Etoposide phosphate

Lymphatic Diseases

Ifosfamide

Prednisolone

Methotrexate

Lymphoma, Non-Hodgkin

Aggression

Lymphoproliferative Disorders

Mesna

Etoposide

Lymphoma

Dexamethasone acetate

Methylprednisolone Hemisuccinate

Isophosphamide mustard

Additional relevant MeSH terms:

Neoplasms

Neoplasms by Histologic Type

Immune System Diseases

ClinicalTrials.gov processed this record on October 07, 2008

Sponsored by:	Arbeitsgemeinschaft medikamentoese Tumortherapie
Information provided by:	Arbeitsgemeinschaft medikamentoese Tumortherapie
ClinicalTrials.gov Identifier:	NCT00517894